Literature DB >> 21167930

Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer's disease.

Marina Saresella1, Elena Calabrese, Ivana Marventano, Federica Piancone, Andrea Gatti, Margherita Alberoni, Raffaello Nemni, Mario Clerici.   

Abstract

Inflammatory mediators are responsible for the neuroinflammation observed in Alzheimer's disease (AD), a phenomenon that might be the culprit of disease or, possibly, a reaction to pathology. To better investigate inflammation in AD we performed an extensive immunophenotypic and functional analysis of amyloid-beta (Aβ) stimulated T lymphocytes in patients with a diagnosis of AD comparing data to those obtained in individuals with mild cognitive impairment (MCI) or aged-matched healthy individuals (HC). Results showed that IL-21- and IL-9-producing Aβ stimulated CD4(+) T cells, as well as IL-23- and IL-6-producing monocytes and CD4(+) T cells expressing the RORγ and NFATc1 transcriptional factors (TF), were significantly increased, whereas IL-10-producing monocytes were decreased in AD. Notably, GATA-3 TF-expressing CD4(+) T lymphocytes were significantly increased in MCI alone. Analysis of the post-thymic differentiation pathway indicated that Aβ specific naïve and central memory CD4(+) T lymphocytes were diminished whereas effector memory and terminally differentiated CD4(+) T lymphocytes were increased in AD and MCI compared to HC. Data herein indicate that cytokines (IL-21, IL-6, IL-23) and TF (RORγ) involved in the differentiation of Th-17 cells), as well as cytokines (IL-21, IL-22) generated by such cells, and IL-9, produced by Th-9 cells, are significantly increased in AD. This is accompanied by a shift of post-thymic differentiation pathways favoring the accumulation of differentiated, effector T lymphocytes. These data shed light on the nature of AD-associated neuroinflammation. A better understanding of the complexity of this phenomenon could facilitate the search for novel therapeutic strategies.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21167930     DOI: 10.1016/j.bbi.2010.12.004

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  56 in total

1.  Th9 and Th22 immune response in young patients with type 1 diabetes.

Authors:  Monika Ryba-Stanisławowska; Paulina Werner; Agnieszka Brandt; Małgorzata Myśliwiec; Jolanta Myśliwska
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

2.  DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.

Authors:  Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Larry D Anderson; Olaf Stüve; Todd N Eagar; Roger N Rosenberg
Journal:  Cell Mol Neurobiol       Date:  2011-04-06       Impact factor: 5.046

3.  Neutralization of IL-17 rescues amyloid-β-induced neuroinflammation and memory impairment.

Authors:  Claudia Cristiano; Floriana Volpicelli; Pellegrino Lippiello; Benedetta Buono; Federica Raucci; Marialuisa Piccolo; Asif Jilani Iqbal; Carlo Irace; Maria Concetta Miniaci; Carla Perrone Capano; Antonio Calignano; Nicola Mascolo; Francesco Maione
Journal:  Br J Pharmacol       Date:  2019-03-03       Impact factor: 8.739

4.  Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice.

Authors:  Tomomi Kiyota; Jatin Machhi; Yaman Lu; Bhagyalaxmi Dyavarshetty; Maryam Nemati; Izumi Yokoyama; R L Mosley; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2018-03-17       Impact factor: 3.478

5.  A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson's disease in older people: an EXosomes in PArkiNson Disease (EXPAND) ancillary study.

Authors:  Riccardo Calvani; Anna Picca; Giovanni Landi; Federico Marini; Alessandra Biancolillo; Hélio José Coelho-Junior; Jacopo Gervasoni; Silvia Persichilli; Aniello Primiano; Annalaura Arcidiacono; Andrea Urbani; Maurizio Bossola; Anna Rita Bentivoglio; Matteo Cesari; Roberto Bernabei; Maria Rita Lo Monaco; Emanuele Marzetti
Journal:  Geroscience       Date:  2020-05-26       Impact factor: 7.713

6.  IL-33 and its decoy sST2 in patients with Alzheimer's disease and mild cognitive impairment.

Authors:  Marina Saresella; Ivana Marventano; Federica Piancone; Francesca La Rosa; Daniela Galimberti; Chiara Fenoglio; Elio Scarpini; Mario Clerici
Journal:  J Neuroinflammation       Date:  2020-06-06       Impact factor: 8.322

7.  Interleukin 9 alterations linked to alzheimer disease in african americans.

Authors:  Whitney Wharton; Alexander L Kollhoff; Umesh Gangishetti; Danielle D Verble; Samsara Upadhya; Henrik Zetterberg; Veena Kumar; Kelly D Watts; Andrea J Kippels; Marla Gearing; J Christina Howell; Monica W Parker; William T Hu
Journal:  Ann Neurol       Date:  2019-07-22       Impact factor: 10.422

Review 8.  T Cells-Protective or Pathogenic in Alzheimer's Disease?

Authors:  Róisín M McManus; Kingston H G Mills; Marina A Lynch
Journal:  J Neuroimmune Pharmacol       Date:  2015-05-10       Impact factor: 4.147

9.  IL-9-producing Th9 cells may participate in pathogenesis of Takayasu's arteritis.

Authors:  Li-Li Pan; Juan Du; Na Gao; Hua Liao; Jin Wan; Wei-Ping Ci; Chun Yang; Tian Wang
Journal:  Clin Rheumatol       Date:  2016-09-15       Impact factor: 2.980

Review 10.  Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system.

Authors:  Elsa How Shing Koy; Pierre Labauge; Athan Baillet; Clément Prati; Hubert Marotte; Yves-Marie Pers
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-07-09       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.